Glaukos Co. (NYSE:GKOS) Stock Position Lowered by Natixis Advisors LLC

Natixis Advisors LLC trimmed its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 9.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 34,299 shares of the medical instruments supplier's stock after selling 3,439 shares during the period. Natixis Advisors LLC owned 0.06% of Glaukos worth $5,143,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wellington Management Group LLP lifted its holdings in Glaukos by 294.5% in the third quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier's stock worth $284,501,000 after acquiring an additional 1,630,270 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Glaukos by 47.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier's stock worth $83,609,000 after purchasing an additional 207,338 shares during the period. Loomis Sayles & Co. L P boosted its position in Glaukos by 21.6% during the 3rd quarter. Loomis Sayles & Co. L P now owns 673,751 shares of the medical instruments supplier's stock valued at $87,776,000 after purchasing an additional 119,527 shares during the period. Raymond James Financial Inc. bought a new position in Glaukos during the 4th quarter worth $16,910,000. Finally, State Street Corp increased its position in Glaukos by 5.3% in the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier's stock worth $254,626,000 after buying an additional 98,109 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Glaukos Price Performance

Shares of GKOS stock traded down $3.65 during mid-day trading on Wednesday, hitting $103.26. 479,979 shares of the stock traded hands, compared to its average volume of 584,967. Glaukos Co. has a twelve month low of $87.59 and a twelve month high of $163.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The company's 50-day simple moving average is $133.61 and its 200-day simple moving average is $136.29. The firm has a market cap of $5.84 billion, a price-to-earnings ratio of -35.98 and a beta of 0.99.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. As a group, equities research analysts expect that Glaukos Co. will post -1.08 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on GKOS. UBS Group assumed coverage on shares of Glaukos in a report on Friday, December 6th. They set a "buy" rating and a $182.00 price target for the company. Truist Financial boosted their target price on shares of Glaukos from $152.00 to $185.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. Wells Fargo & Company raised their price target on shares of Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Piper Sandler reaffirmed an "overweight" rating and set a $180.00 price target (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. Finally, Stifel Nicolaus increased their price objective on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a report on Tuesday, December 31st. One research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Glaukos has an average rating of "Moderate Buy" and an average price target of $163.25.

Insider Buying and Selling

In other news, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares of the company's stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 6.40% of the company's stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.